Objective: To investigate the survival outcomes for non-Hodgkin lymphoma (NHL) in HIV-infected vs. uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy.
Introduction
HIV-infected persons continue to endure a significantly elevated risk for developing non-Hodgkin lymphoma (NHL) as compared with the general population in the era of combined antiretroviral therapy (cART) [1, 2] . However, substantial improvements in survival of patients with HIV-related NHL have been reported [3, 4] . Although several clinical studies [3, [5] [6] [7] suggested comparable survival of patients with HIV-related NHL treated with cART and chemotherapy to that of high-grade NHL in HIV-uninfected individuals, these studies often included highly selected patient populations from clinical trials or tertiary clinical centers, which may have limited generalizability. Furthermore, differential access to healthcare by HIV-infection status may also introduce confounding. To address these limitations, we sought to determine the association between HIV-infection status and mortality outcome after NHL diagnosis in the cART era in an insured, population-based setting of Kaiser Permanente California, an integrated healthcare organization. Prognostic factors in HIV-related NHL were also examined.
Methods

Study population
Kaiser Permanente is the largest managed care organization in California, USA, serving over six million ethnically and socioeconomically diverse members. Incident cases of NHLs diagnosed between 1996 and 2005 were identified from Kaiser Permanente's Surveillance, Epidemiology and End Result (SEER)-affiliated cancer registries using SEER recodes 33040, 33041, and 33042. The histologic subtypes of NHL were identified using International Classification of Diseases for Oncology, 3rd ed. (ICD-O-3) histology codes 9678-9680 and 9684 for diffuse large B-cell lymphoma (DLBCL); codes 9687 and 9826 for Burkitt's lymphoma; and codes 9690, 9691, 9695, and 9698 for follicular lymphoma. Central nervous system (CNS) involvement was identified using ICD-O-3 site code C70.x, C71.x, and C72.x. The cancer registries also provided date of diagnosis, race/ethnicity, stage, and initial course of therapy (e.g., chemotherapy).
HIV-infection status for incident NHL patients was ascertained via record linkage with the Kaiser Permanente HIV registries using the patient's unique medical record number. The sensitivity and specificity of the Kaiser Permanente HIV registry are estimated to be at least 95% and at least 99%, respectively. Patients included in the HIV registries were initially screened using electronic databases, followed by chart review, confirmation with clinical staff at the corresponding medical centers, or both. This study was approved by the Kaiser Permanente California Institutional Review Boards.
Outcome assessment
The primary and secondary endpoint of interest was 2-year all-cause mortality and 2-year lymphoma-specific mortality after NHL diagnosis, respectively. Causes and dates of death were ascertained from Kaiser Permanente hospital death and membership files, California State death certificates, and Social Security administration death files. Lymphoma-specific deaths were identified from California State death certificates using ICD-9 (200, 201, and 202; for deaths prior to 1999) and ICD-10 codes (C82, C83, C84, C85, C88, C91, and C96, and in addition, B21.1, B21.2, C82, C83, and C85 for HIVinfected patients; for deaths in 1999 and forward). Fourteen deaths (three HIV-infected and 11 HIVuninfected) were excluded from the secondary analysis of lymphoma-specific mortality due to missing information on cause of death.
Measurements of other covariates
Data for several additional covariates of interest were collected from Kaiser Permanente's electronic medical databases. Charlson's comorbidity index [8] was calculated using inpatient diagnosis codes and modified to exclude the diagnosis of AIDS. HIV-specific characteristics examined included HIV transmission risk group and prior AIDS-defining illness (both ascertained from the HIV registry), prior cART use (defined by Department of Health and Human Services published guidelines [9] and captured by Kaiser Permanente pharmacy databases), CD4 cell count and HIV RNA level (obtained from Kaiser Permanente laboratory databases). All characteristics were measured at the time of NHL diagnosis.
Statistical analysis
Distributions of demographics, lymphoma and HIVrelated characteristics, and their univariate associations with mortality outcomes were calculated by HIVinfection status. To study the association between HIVinfection status and mortality outcomes, multivariable Poisson regression with robust error variance was used to directly estimate the relative risk (RR) [10] . Factors associated with HIV-infection status and 2-year mortality in the univariate analyses with a P value below 0.10 were included in the multivariable analyses (these included year of diagnosis, age, sex, race/ethnicity, Charlson's index, stage, NHL histology subtype, and CNS involvement). The impact of adjusting for initial treatment of chemotherapy was also considered in a separate model. Stratified analyses were then performed for: white and nonwhite race; lymphoma stages I/II and stages III/IV; and DLBCL, Burkitt's lymphoma, and other NHL histologic subtypes. HIV-infected patients were also stratified by CD4 cell count (<200 cells/ml and !200 cells/ml) at NHL diagnosis and whether NHL was the initial AIDSdefining illness (i.e. no prior AIDS-defining illness) and their mortality was compared with mortality of HIVuninfected patients.
Among HIV-infected NHL patients, the prognostic value of year of diagnosis, age, sex, race/ethnicity, Charlson's index, stage, NHL histology subtype, CNS involvement, CD4 cell count, HIV RNA level, prior AIDS-defining illness, and duration of cART use was evaluated using multivariable Poisson models with robust error variance. Calendar period was included to assess the survival trend of HIV-infected NHL patients. All analyses were conducted using SAS statistical software version 9.1.3 (Statistical Analyses System Inc., Cary, North Carolina, USA).
Results
A total of 259 HIV-infected and 8230 HIV-uninfected incident NHL patients were identified between 1996 and 2005. Characteristics of the NHL patients differed by HIV-infection status, for example, HIV-infected NHL patients were more likely to be diagnosed at a younger age and were of black or Hispanic race/ethnicity (Table 1) . Fifty-one percent of the HIV-infected patients were diagnosed with a CD4 cell count of less than 200 cells/ml; 52% had a prior AIDS-defining illness and 58% had been previously treated with cART (Table 1) .
HIV-infection status and 2-year mortality
Among HIV-infected patients, 59% died within 2 years after NHL diagnosis as compared with 30% of HIVuninfected patients ( Table 2 , top). Of deaths among HIVinfected patients, 58% were lymphoma-related, compared with 76% of deaths in HIV-uninfected patients ( Table 2 ). In the multivariable analyses, HIV-infection status was associated with a doubled 2-year all-cause mortality risk [relative risk (RR) ¼ 2.0, 95% confidence interval (CI) 1.7-2.3, P < 0.001, Table 2 ]. Further adjusting for the initial treatment of chemotherapy after NHL diagnosis did not materially affect the results (RR HIV þ ¼ 1.6, 95% CI 1.4-1.8). When HIV-infected patients were further categorized by their CD4 cell count levels and prior clinical AIDS status, elevated all-cause mortality risk compared with HIV-uninfected patients was observed among all subgroups examined ( Table 2 ). In the stratified analyses, the elevated mortality risk for HIVinfected patients was consistently observed across race groups, NHL stages, and histologic subtypes ( Table 2) .
HIV-infected patients were also at increased risk for 2-year lymphoma-specific mortality (RR ¼ 1.4, 95% CI 1.1-1.7, P ¼ 0.001, Table 2 ). The risk for lymphomaspecific mortality was particularly high for those with CD4 cell count below 200 cells/ml, prior AIDS-defining illness, or both. On the contrary, those who had CD4 cell count of at least 200 cells/ml and no prior AIDSdefining illness appeared to have comparable lymphomaspecific mortality with that of HIV-uninfected patients (RR ¼ 1.1, 95% CI 0.7-1.9, P ¼ 0.66).
Prognostic factors for mortality in HIV-related non-Hodgkin lymphoma
Among HIV-infected patients, Burkitt's lymphoma (RR ¼ 1.3, 95% CI 1.0-1.7) and prior AIDS-defining illness (RR ¼ 1.4, 95% CI 1.1-1.9) were significantly associated with an increased all-cause mortality. In addition, nonwhite race (RR ¼ 1.2, 95% CI 1.0-1.5), low CD4 cell count (<200 cells/ml) at NHL diagnosis (RR ¼ 1.2, 95% CI 1.0-1.6) and other non-DLBCL histologic subtype (RR ¼ 1.2, 95% CI 1.0-1.6) also appeared to be associated with elevated all-cause mortality (P < 0.10). We observed no calendar era changes in overall mortality for these patients. For lymphomaspecific mortality, none of the factors examined were statistically significant prognostic factors, although some demonstrated similar magnitude of RR as in the analysis for all-cause mortality (data not shown).
Discussion
Our study, spanning a 10-year period since 1996, represents one of the largest to include HIV-infected and HIV-uninfected NHL patients identified from the same health system. We observed a 2-year mortality of 60% for HIV-infected NHL patients, a rate that is comparable to those (55-78%) seen in other observational studies [11] [12] [13] [14] in the cART era. We found that overall, HIV-infected NHL patients continued to have a significantly elevated all-cause and lymphoma-specific mortality compared with NHL patients in the general population. However, HIV-infected patients with better controlled HIV disease, that is, those whose NHL was the first AIDS-defining illness and was developed with a CD4 cell count level of 200 cells/ml or greater did not have an increased risk for lymphoma-specific mortality compared with HIV-uninfected patients. This finding supports aggressive HIV disease management strategy for patients infected with HIV and potentially earlier start of cART [15, 16] .
A previous study [17] found similar survival for HIVinfected and HIV-uninfected NHL patients when response to chemotherapy was adjusted. The authors concluded that the lower complete remission rate achieved by the HIV-infected patients was the cause for the inferior survival for HIV-infected patients. It is possible that the low CD4 cell counts, which can be seen with advanced HIV disease, may be a predictor for undesirable treatment response or toxicity. However, studies [6, [18] [19] [20] evaluating the relationship of CD4 cell count and lymphoma treatment response were mixed. Future studies should further investigate the effect of HIV disease management on NHL treatment experience.
We found that non-DLBCL lymphoma histologic subtype, prior AIDS-defining illness, nonwhite race, and CD4 cell count below 200 cells/ml were prognostic factors for all-cause mortality in HIV-infected patients. The prognostic role of lymphoma characteristics in HIVinfected NHL has been consistently reported in the cART era [18, [21] [22] [23] . However, contrary to the literature, more advanced stage disease was not a predictor for all-cause mortality among HIV-infected patients. The prognostic role of HIV disease factors (such as CD4 cell count, HIV RNA level, and cARTuse) in NHL has been less clear [18] . Several population-based studies [11, 13, 23] of HIV-related NHL, including the present one, reported low CD4 cell count and prior AIDS-defining illness to be important prognostic factors in the cART era. On the contrary, use of cART prior to NHL diagnosis was not predictive of overall survival (OS) in this study as well as others [12] [13] [14] 24] .
There are several potential limitations in our study that should be considered when interpreting our results. Because of the observational study design, we did not have information on CD4 cell counts or HIV RNA levels at NHL diagnosis for many HIV-infected patients 1768 AIDS 2010, Vol 24 No 11 Data are given in mean (SD).
( Table 1) , which could potentially have resulted in bias if survival was different for patients with and without such measurements. Another potential limitation came from the use of death certificate to determine lymphoma-specific death. As it was possible that some of the NHL-related deaths were vaguely coded with an underlying cause of HIV/AIDS, results for lymphomaspecific mortality should be interpreted with caution. Finally, generalizability of our results to persons without health insurance may be limited, or to other healthcare systems that do not have an integrated healthcare model.
Conclusion
Our study showed a poor 2-year OS, approaching only 40% for HIV-infected patients after NHL diagnosis in the cART era, with no clear improvement over the 10-year study period. However, HIV-infected patients with higher CD4 cell counts and no prior AIDSdefining illness had a similar risk for lymphomaspecific death as compared with NHL in the general population. These results emphasize the importance in preserving the immune function during the course of HIV disease management, and further evaluating optimal treatment options for HIV-infected NHL patients with severely suppressed immunity, which account for 50% of the HIV-related NHL in the cART era. Models adjusted for year of diagnosis (1996-1999, 2000-2002, and 2003-2005) , age (<40, 40-59, and !60 years), sex, race/ethnicity (white, black, Asian, Hispanic, and other/unknown), modified Charlson's index excluding AIDS (0, 1-4, and !5), stage of NHL (I-II, III, and unknown), CNS involvement, and NHL histologic subtype (diffuse large B-cell, Burkitt's, follicular, and others). For the stratified analyses, the stratification factor was not included in the model. CI, confidence interval; NHL, non-Hodgkin lymphoma; RR, relative risk. a Other causes of death for HIV-infected patients included HIV/AIDS-related events (n ¼ 58), myocardial infraction (n ¼ 2), respiratory distress syndrome (n ¼ 1), myeloid leukemia (n ¼ 1), injury (n ¼ 1), and unknown (n ¼ 3).
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